TuBerculosis Vaccine Initiative (TBVI) is a non-profit foundation that facilitates the discovery and development of new, safe and effective TB vaccines that are accessible and affordable for all people. As a Product Development Partnership (PDP), TBVI integrates, translates and prioritises R&D efforts to discover and develop new TB vaccines and biomarkers for global use. TBVI provides a range of key services that support the R&D efforts of its consortium partners. TBVI does not have its own commercial interests. Ownership of vaccine candidates and biomarkers and any intellectual property rights remain with researchers and vaccine developers.
The TBVI consortium includes more than 50 partners from academia, research institutes and private industry in the TB vaccine field. Key stakeholders include the European Commission (EC), the World Health Organization (WHO), Aeras, the Bill & Melinda Gates Foundation (BMGF), the European and Developing Countries Clinical Trials Partnership (EDCTP), the European Investment Bank (EIB), the governments of Norway, United Kingdom and vaccine industry companies. The governments of Switzerland, South Korea and Australia provide co-funding through the TBVAC2020 project.